HC Wainwright Reiterates Buy Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $10.00 price target on the stock.

GOSS has been the topic of several other research reports. Wedbush began coverage on shares of Gossamer Bio in a research report on Friday, April 5th. They set an “outperform” rating and a $4.00 price target on the stock. The Goldman Sachs Group lowered their target price on Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Gossamer Bio in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.65.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS traded up $0.03 during trading on Monday, reaching $0.77. The company had a trading volume of 7,378,047 shares, compared to its average volume of 1,309,957. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 3.14. Gossamer Bio has a twelve month low of $0.45 and a twelve month high of $1.88. The stock has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $0.93. The stock has a market capitalization of $173.33 million, a PE ratio of -0.54 and a beta of 1.84.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). As a group, sell-side analysts predict that Gossamer Bio will post -0.75 earnings per share for the current year.

Insider Transactions at Gossamer Bio

In other news, CEO Faheem Hasnain sold 23,172 shares of the stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total transaction of $26,879.52. Following the transaction, the chief executive officer now owns 120,293 shares of the company’s stock, valued at $139,539.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 33,620 shares of company stock valued at $39,682. Insiders own 9.50% of the company’s stock.

Institutional Trading of Gossamer Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Sivia Capital Partners LLC bought a new stake in shares of Gossamer Bio during the 1st quarter valued at about $29,000. Financial Advocates Investment Management acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth approximately $61,000. Bank of New York Mellon Corp boosted its position in Gossamer Bio by 178.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock valued at $76,000 after purchasing an additional 58,428 shares during the period. Citigroup Inc. grew its stake in Gossamer Bio by 9,916.9% during the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock worth $164,000 after buying an additional 194,768 shares during the last quarter. Finally, Kynam Capital Management LP bought a new stake in Gossamer Bio in the 3rd quarter valued at about $208,000. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.